Evidence map›Paper›PMID 42689362›Full record

ReviewChemistry & biodiversity2026

Progress in Synthesis and Pharmacology of Telmisartan.

Megha, Richa Srivastava, Ram Singh

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

MeghaDepartment of Applied Chemistry, Delhi Technological University, Delhi, India.
Richa SrivastavaDepartment of Applied Chemistry, Delhi Technological University, Delhi, India.ORCID https://orcid.org/0000-0002-7817-4874
Ram SinghDepartment of Applied Chemistry, Delhi Technological University, Delhi, India.ORCID https://orcid.org/0000-0002-7887-2138

Funding

Delhi Technological University
6 · The paper itself

Abstract

Telmisartan is a benzimidazole derivative and a well-known drug to treat hypertension. This is an angiotensin II receptor blocker (ARB) which helps to relax blood vessels. Studies have shown that telmisartan is effective in reducing cardiovascular disease, with a safety and efficacy profile. This review paper provides an overall understanding of telmisartan as an antihypertensive drug. The goal is to highlight the synthetic methodology of telmisartan, from its first synthesis in 1993. This review also discusses its two mechanisms of action: the Renin-Angiotensin-Aldosterone System (RAAS) inhibitor and partial agonist activity at the Peroxisome Proliferator-activated receptor gamma (PPARγ) receptor. Effective repurposing of this drug for various diseases like chronic kidney illness, diabetes, fatty liver, and Alzheimer's has also been discussed.

Indexed as

Angiotensin II Type 1 Receptor BlockersAntihypertensive AgentsBenzimidazolesBenzoatesTelmisartanAnimalsHumansHypertensionPPAR gammaRenin-Angiotensin SystemAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsBenzimidazolesBenzoatesPPAR gammaTelmisartanAngiotensin receptor blockercardiovascular diseasesdiabeteshypertensionperoxisome proliferator‐activated receptor gammaRenin‐Angiotensin‐Aldosterone systemtelmisartan

Identifiers

PMID42689362
PMCPMC13539479

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.